Nuformix (LON:NFX) Shares Down 12.7% – Should You Sell?

Nuformix plc (LON:NFX) shares fell 12.7% during trading on Friday . The stock traded as low as GBX 0.17 and last traded at GBX 0.17. 19,609,008 shares traded hands during mid-day trading, a decline of 49% from the average session volume of 38,145,949 shares. The stock had previously closed at GBX 0.20.

Nuformix Price Performance

The company has a market cap of £5.22 million, a PE ratio of -5.09 and a beta of 1.55. The company has a 50-day moving average of GBX 0.20 and a 200 day moving average of GBX 0.25.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.